REGN Regeneron Pharmaceuticals, Inc. stock chart & analysis
Conviction 24HealthcareScan · Fri, Nov 6, 2026Regeneron Pharmaceuticals, Inc. (REGN) closed at $904.35 (+0.16%) on Nov 6, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 63, RS Rating 92, -8.8% from its 52-week high, +17.2% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Financials as of Wed, Sep 30, 2026 · quarterly.
REGN technical analysis
Trend
REGN is in an uptrend: price is above the 50-day, which is above the 200-day moving average. It closed 12.4% above the 50-day ($804.38) and 21.8% above the 200-day ($742.33). ADX(14) at 35 points to a strong, established trend. It meets 6 of 8 trend-template criteria.
Momentum
RSI(14) is 63, in the bullish half of its range. The MACD histogram is positive. Its RS Rating of 92 puts its weighted 12-month performance ahead of about 92% of the US market.
Volume and volatility
Volume on the latest session ran 1.1× its 20-day average. It trades about $809.8M a day on average. ATR(14) is $31.38, 3.5% of price — its typical daily range. On-balance volume is trending up. Chaikin Money Flow (0.16) shows accumulation.
Key levels
The chart pattern's support is $722.83 and its resistance $908.63. The 52-week range is $591.52 to $991.73; price is 8.8% below the high and 52.9% above the low. The VWAP anchored at the 52-week high is $924.85, above price.
Performance
REGN returned -2.5% (1 week), +22.3% (1 month), +11.9% (3 months), +26.5% (6 months), +40.4% (1 year), +17.2% (year to date).
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Pharmaceutical Preparations · Listed 1991 · 15,410 employees
Congress activity
Disclosed STOCK Act trades in REGN · 10 recent
| Member | Side | Amount | Traded | Filed | PTR |
|---|---|---|---|---|---|
 Alan Armstrong senate · R · OK · traded 2026-03-27 | Buy | $1K–$15K | 2026-03-27 | 2026-07-21 | |
 Gilbert Cisneros house · CA · traded 2026-05-15 | Sell | $1K–$15K | 2026-05-15 | 2026-06-05 | |
Gilbert Cisneros house · CA · traded 2025-11-18 | Buy | $1K–$15K | 2025-11-18 | 2025-12-12 | |
 Rob Bresnahan house · PA · traded 2025-05-15 | Buy | $1K–$15K | 2025-05-15 | 2025-06-09 | |
 Byron Donalds house · R · FL · traded 2025-04-10 | Sell | $1K–$15K | 2025-04-10 | 2025-05-24 | |
 Julie Johnson house · D · TX · traded 2025-04-01 | Sell | $1K–$15K | 2025-04-01 | 2025-05-14 | |
 Jefferson Shreve house · R · IN · traded 2025-04-07 | Sell | $15K–$50K | 2025-04-07 | 2025-05-08 | |
Rob Bresnahan house · PA · traded 2025-04-08 | Sell | $1K–$15K | 2025-04-08 | 2025-05-08 | |
Rob Bresnahan house · PA · traded 2025-02-25 | Sell | $1K–$15K | 2025-02-25 | 2025-03-27 | |
Julie Johnson house · D · TX · traded 2025-02-12 | Sell | $1K–$15K | 2025-02-12 | 2025-03-12 |
Insider activity
SEC Form 4 transactions in REGN · open-market 7 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Pitofsky Jason SVP Controller · Common Stock · 2026-11-04 | Exercise | 1.5K | $1.1M | 2026-11-04 | 2026-11-06 |
Pitofsky Jason SVP Controller · Common Stock · 2026-11-04 | Exercise | 1.48K | $953K | 2026-11-04 | 2026-11-06 |
Pitofsky Jason SVP Controller · Common Stock · 2026-11-04 | Exercise | 905 | $445K | 2026-11-04 | 2026-11-06 |
Pitofsky Jason SVP Controller · Common Stock · 2026-11-04 | Sell | 439 | $412K | 2026-11-04 | 2026-11-06 |
Pitofsky Jason SVP Controller · Common Stock · 2026-11-04 | Sell | 575 | $541K | 2026-11-04 | 2026-11-06 |
Pitofsky Jason SVP Controller · Common Stock · 2026-11-04 | Sell | 982 | $925K | 2026-11-04 | 2026-11-06 |
Pitofsky Jason SVP Controller · Common Stock · 2026-11-04 | Sell | 1.22K | $1.1M | 2026-11-04 | 2026-11-06 |
Pitofsky Jason SVP Controller · Common Stock · 2026-11-04 | Sell | 529 | $499K | 2026-11-04 | 2026-11-06 |
Pitofsky Jason SVP Controller · Common Stock · 2026-11-04 | Sell | 108 | $102K | 2026-11-04 | 2026-11-06 |
Pitofsky Jason SVP Controller · Common Stock · 2026-11-04 | Sell | 35 | $33K | 2026-11-04 | 2026-11-06 |
SEC filings
EDGAR filings in REGN · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.